Retrospective analysis of the clinical outcome from TCGA-LGG and TCGA-GBM datasets suggested that LBX2-AS1 high expression group (n = 337) have a shorter disease-free survival compared with LBX2-AS1 low expression group (n = 335) (Fig. 1d). The gene discussed is LBX2; the disease is glioblastoma.